KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

NovoCure (NVCR) Interest & Investment Income (2021 - 2026)

NovoCure's Interest & Investment Income history spans 6 years, with the latest figure at -$1.8 million for Q1 2026.

  • On a quarterly basis, Interest & Investment Income fell 124.28% to -$1.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $8.1 million, a 78.01% decrease, with the full-year FY2025 number at $17.6 million, down 55.38% from a year prior.
  • Interest & Investment Income hit -$1.8 million in Q1 2026 for NovoCure, down from -$561000.0 in the prior quarter.
  • Over the last five years, Interest & Investment Income for NVCR hit a ceiling of $18.5 million in Q4 2022 and a floor of -$1.8 million in Q1 2026.
  • Historically, Interest & Investment Income has averaged $7.7 million across 5 years, with a median of $8.8 million in 2023.
  • Biggest five-year swings in Interest & Investment Income: soared 739.45% in 2023 and later plummeted 124.28% in 2026.
  • Tracing NVCR's Interest & Investment Income over 5 years: stood at $18.5 million in 2022, then fell by 28.87% to $13.2 million in 2023, then crashed by 38.57% to $8.1 million in 2024, then plummeted by 106.93% to -$561000.0 in 2025, then tumbled by 227.63% to -$1.8 million in 2026.
  • Business Quant data shows Interest & Investment Income for NVCR at -$1.8 million in Q1 2026, -$561000.0 in Q4 2025, and $6.0 million in Q3 2025.